A Phase Ib, prospective assessing the potential early predictors of the 12-week treatment response estimated by using the MRI-based proton-density fat fraction (PDFF) of MET409 in patients with non-alcoholic steatohepatitis (NASH)
Latest Information Update: 15 Oct 2021
At a glance
- Drugs MET-409 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacodynamics
- 15 Oct 2021 New trial record